New Category 3 CPT Code for Eye-Tracking Test for Concussion Diagnosis 

  • Brain Concussion
  • Brain Injury

The American Medical Association (AMA) has confirmed the addition of a new code for an eye-tracking diagnostic procedure for concussion (Eyebox; Oculogica, New York, New York).The category 3 CPT Code, 0X17T, eye movement analysis test without spatial calibration,allows clinicians to appropriately report the services related exclusively to the eye exam. 

The under 4-minute test is unique in that it uses non-spatially calibrated eye tracking, is non-invasive, does not require a baseline test and is authorized by theFood and Drug Administration (FDA). The eyebox obtained marketing authorization in December 2018 as an aid in the diagnosis of concussion or a mild traumatic brain injury (mTBI) and launched in January 2019.

“Obtaining the CPT code is an important achievement and builds on eyebox’s position as the first and only FDA-cleared objective, baseline-free aid in diagnosis of concussion. This new CPT code is vital to Oculogica’s goals of broadening access to clinically validated, multi-modal tools for patients and healthcare practitioners to improve the diagnosis of concussion”, said Rosina Samadani, PhD, CEO of Oculogica. “The introduction of this code is an important first step in the establishment of widespread insurance coverage and reimbursement for the eyebox test.”

The safety and efficacy study (NCT03280056) demonstrated the eye tracking test high sensitivity to the presence of concussion and ability to provide objective information to aid in the evaluation of individuals with suspected mTBI. Studies were initiated to assess applicability in concussion management and treatment and continuing to explore potential utility in the diagnosis of other neurologic conditions, such as elevated intracranial pressure.

The approved new code will be published by the AMA CPT Editorial Panel January 1, 2020 and become effective July 1, 2020.

Phase 3 Pivotal Study of Trofinetide for Rett Syndrome Initiated

Previous News Article

FDA Approves Diroximel Fumarate—A Second Generation Fumarate With Fewer Side Effects—for Treatment of Multiple Sclerosis

Next News Article
This Month's Issue
Utility of Autoantibody Profiles

Shailee S. Shah, MD, and Andrew McKeon, MD

Stiff-Person Syndrome

Jakai D. Nolan, DO, MPH, and Jacqueline A. Nicholas, MD, MPH